Summary
The controlled clinical triad is designed not to discover new drug effects, but to verify those effects, about which prior knowledge exists adequate for formulating exact null hypotheses. Therapeutic effects always meet this requirement. The question of a drug's clinical toxicity is essentially vague and open-ended and, therefore, ineligible for being fully answered by controlled trial. It can examine only those adverse drug effects which are predicted or anticipated, which occur with a certain frequency compatible with a practical trial size, and which do not pose ethical restrictions to human experimentation. Most toxic drug effects must be assessed empirically, i. e., by incompletely controlled observation or survey of events as they happen during ordinary drug use. This does not mean arbitrary collection of isolated data, but requires purposeful, systematic and coordinated procedures. Observational evidence is circumstantial and disputable from a strictly scientific viewpoint. Nevertheless, if observational data satisfy certain criteria, they contribute to decisions which are reasonable and practically useful by minimizing the risks for patients from adverse drug effects.
Similar content being viewed by others
References
Atkins, H.: Conduct of a controlled clinical trial. Brit. med. J. 1956 II, 377–379.
Daniel, D. G., H. Campbell, and A. C. Turnbull: Puerperal thromboembolism and suppression of lactation. Lancet 1967 II, 287–289.
Drill, V. A., and D. W. Calhoun: Oral contraceptives and thromboembolic disease. J.A.M.A. 206, 77–84 (1968).
Fisher, R. A.: The design of experiments, 8th ed., pp. 15–17. Edinburgh and London, New York: Oliver and Boyd, Ltd., Hafner Publishing Company 1966.
Hill, A. B.: Principles of medical statistics. 8th ed., New York: Oxford University Press 1966.
The environment and disease: association or causation? Proc. roy. Soc. Med. 58, 294–300 (1965).
Jiji, R. M., E. J. Gangarosa, and F. De La Macorra: Chloramphenicol and its sulfamoyl analogue. Report of reversible erythropoietic toxicity in healthy volunteers. Arch. intern. Med. 111, 70–82 (1963).
Mainland, D.: Elementary medical statistics, p. 317. Philadelphia: W.B. Saunders Company 1952.
Medical Research Council. Preliminary communication by a subcommittee: Risk of thromboembolic disease in women taking oral contraceptives. Brit. med. J. 1967 II, 355–359.
Meyers, F. H., E. Jawetz, and A. Goldfien: A review of medical pharmacology, p. 42. Los Altos: Lange Medical Publications 1968.
Oliver, M. F.: Thrombosis and oestrogens. Lancet 1967 II, 510–511.
Taussig, H. B.: A study of the German outbreak of phocomelia. J.A.M.A. 180, 1106–1114 (1962).
Versey, M. P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease. Brit. med. J. 2, 199–205 (1968).
Voss, H. E., A. P. Remond and B. B. Levine: Clinical detection of the potential allergic reactor to penicillin by immunological tests. J.A.M.A. 196, 679–683 (1966).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wendel, H.A. Adverse drug effects and the controlled clinical trial. Pharmacol. Clin. 2, 58–62 (1969). https://doi.org/10.1007/BF00404188
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00404188